 |
|
|
| |
Safety and Efficacy of Nivolumab in Patients With Advanced Hepatocellular
Carcinoma: Interim Analysis of the Phase 1/2 CheckMate 040 Study
|
| |
| |
Reported by Jules Levin
APASL 2017
26th Conference of the Asian Pacific Association for the Study of the Liver (APASL);
February 15-19, 2017; Shanghai, China
AASLD/2016: Nivolumab in Patients With Advanced Hepatocellular Carcinoma: the CheckMate 040 Study - (11/16/16)
26th Conference of the Asian Pacific Association for the Study of the Liver
2017 APASL, Feb 15-19
Shanghai, China
Ignacio Melero,1 Bruno Sangro,1 Thomas Yau,2 Chiun Hsu,3 Masatoshi Kudo,4 Todd S. Crocenzi,5 Tae-You Kim,6 Su-Pin Choo,7 Jorg Trojan,8 Tim Meyer,9
Theodore H. Welling, III,10 Winnie Yeo,11 Akhil Chopra,12 Jeffrey Anderson,13 Christine dela Cruz,13 Lixin Lang,13 Jaclyn Neely,13 Anthony B. El-Khoueiry14
1Clinica Universidad de Navarra and CIBERehd, Pamplona, Spain; 2University of Hong Kong, Hong Kong, China; 3National Taiwan University Hospital, Taipei, Taiwan; 4Kindai University Faculty of Medicine, Osaka, Japan; 5Providence Cancer Center, Portland, OR, USA; 6Seoul National University Hospital, Seoul,
Korea; 7National Cancer Center, Singapore; 8Goethe University Hospital and Cancer Center, Frankfurt, Germany; 9Royal Free Hospital, London, UK; 10University of Michigan School of Medicine, Ann Arbor, MI, USA; 11Chinese University of Hong Kong, Hong Kong, China; 12Johns Hopkins Singapore International
Medical Centre, Singapore; 13Bristol-Myers Squibb, Princeton, NJ, USA; 14USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
|
| |
|
|
|
|
|
